The Europe Multiple Myeloma Market should witness market growth of 9.1% CAGR during the forecast period (2023-2029).
An increase in R&D activity is contributing to expanding the multiple myeloma market. The growth of the multiple myeloma market will benefit from these opportunities. In addition, an increase in the number of drugs that are both released and approved will further propel the growth rate of the market. Monoclonal antibodies (mAbs), like Empliciti and Darzalex, will act as a major opportunity for the market's growth because they will not only give patients with multiple myeloma a new therapeutic option, but they will also help patients experience fewer relapses, extending the effectiveness of Revlimid and Velcade treatments.
In addition, these patients will also have access to Kyprolis and Ninlaro, two second-generation protease inhibitors, broadening their treatment options. This will affect the market and industry, currently dominated by the proteasome inhibitor Velcade and the immunomodulator Revlimid. Also, growing investments in cutting-edge technologies and a rise in new markets will create more favorable conditions for expanding the multiple myeloma market over the forecast period.
The prevalence of multiple myeloma has been continuously rising in Germany over the past few years, which has increased the demand for cutting-edge therapies. The prevalence of multiple myeloma is higher in older persons, and as Germany's population ages, there will likely be greater demand for medicines for the disease. The market is expanding due to substantial developments in creating novel treatments for multiple myelomas, such as immunomodulatory medicines and monoclonal antibodies. The German healthcare system offers advantageous reimbursement rules for cancer therapies, including medications for multiple myeloma, which is assisting in the market's expansion.
The Germany market dominated the Europe Multiple Myeloma Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $2,529.5 Million by 2029. The UK market is anticipated to grow at a CAGR of 8.2% during (2023-2029). Additionally, The France market would exhibit a CAGR of 9.9% during (2023-2029).
Based on End-user, the market is segmented into Hospitals, Clinics, and Others. Based on Disease Type, the market is segmented into Active Multiple Myeloma and Smoldering Multiple Myeloma. Based on Drug Type, the market is segmented into Protease Inhibitors, Monoclonal Antibody, Chemotherapy and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.
An increase in R&D activity is contributing to expanding the multiple myeloma market. The growth of the multiple myeloma market will benefit from these opportunities. In addition, an increase in the number of drugs that are both released and approved will further propel the growth rate of the market. Monoclonal antibodies (mAbs), like Empliciti and Darzalex, will act as a major opportunity for the market's growth because they will not only give patients with multiple myeloma a new therapeutic option, but they will also help patients experience fewer relapses, extending the effectiveness of Revlimid and Velcade treatments.
In addition, these patients will also have access to Kyprolis and Ninlaro, two second-generation protease inhibitors, broadening their treatment options. This will affect the market and industry, currently dominated by the proteasome inhibitor Velcade and the immunomodulator Revlimid. Also, growing investments in cutting-edge technologies and a rise in new markets will create more favorable conditions for expanding the multiple myeloma market over the forecast period.
The prevalence of multiple myeloma has been continuously rising in Germany over the past few years, which has increased the demand for cutting-edge therapies. The prevalence of multiple myeloma is higher in older persons, and as Germany's population ages, there will likely be greater demand for medicines for the disease. The market is expanding due to substantial developments in creating novel treatments for multiple myelomas, such as immunomodulatory medicines and monoclonal antibodies. The German healthcare system offers advantageous reimbursement rules for cancer therapies, including medications for multiple myeloma, which is assisting in the market's expansion.
The Germany market dominated the Europe Multiple Myeloma Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $2,529.5 Million by 2029. The UK market is anticipated to grow at a CAGR of 8.2% during (2023-2029). Additionally, The France market would exhibit a CAGR of 9.9% during (2023-2029).
Based on End-user, the market is segmented into Hospitals, Clinics, and Others. Based on Disease Type, the market is segmented into Active Multiple Myeloma and Smoldering Multiple Myeloma. Based on Drug Type, the market is segmented into Protease Inhibitors, Monoclonal Antibody, Chemotherapy and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.
Scope of the Study
By End-user
- Hospitals
- Clinics
- Others
By Disease Type
- Active Multiple Myeloma
- Smoldering Multiple Myeloma
By Drug Type
- Protease Inhibitors
- Monoclonal Antibody
- Chemotherapy
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Bristol Myers Squibb Company
- Amgen, Inc.
- AbbVie, Inc.
- Sanofi S.A.
- Johnson & Johnson
- Baxter International, Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Multiple Myeloma Market, by End User
1.4.2 Europe Multiple Myeloma Market, by Disease Type
1.4.3 Europe Multiple Myeloma Market, by Drug Type
1.4.4 Europe Multiple Myeloma Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Analyst's Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. Europe Multiple Myeloma Market by End User
4.1 Europe Hospitals Market by Country
4.2 Europe Clinics Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Multiple Myeloma Market by Disease Type
5.1 Europe Active Multiple Myeloma Market by Country
5.2 Europe Smoldering Multiple Myeloma Market by Country
Chapter 6. Europe Multiple Myeloma Market by Drug Type
6.1 Europe Protease Inhibitors Market by Country
6.2 Europe Monoclonal Antibody Market by Country
6.3 Europe Chemotherapy Market by Country
6.4 Europe Others Market by Country
Chapter 7. Europe Multiple Myeloma Market by Country
7.1 Germany Multiple Myeloma Market
7.1.1 Germany Multiple Myeloma Market by End User
7.1.2 Germany Multiple Myeloma Market by Disease Type
7.1.3 Germany Multiple Myeloma Market by Drug Type
7.2 UK Multiple Myeloma Market
7.2.1 UK Multiple Myeloma Market by End User
7.2.2 UK Multiple Myeloma Market by Disease Type
7.2.3 UK Multiple Myeloma Market by Drug Type
7.3 France Multiple Myeloma Market
7.3.1 France Multiple Myeloma Market by End User
7.3.2 France Multiple Myeloma Market by Disease Type
7.3.3 France Multiple Myeloma Market by Drug Type
7.4 Russia Multiple Myeloma Market
7.4.1 Russia Multiple Myeloma Market by End User
7.4.2 Russia Multiple Myeloma Market by Disease Type
7.4.3 Russia Multiple Myeloma Market by Drug Type
7.5 Spain Multiple Myeloma Market
7.5.1 Spain Multiple Myeloma Market by End User
7.5.2 Spain Multiple Myeloma Market by Disease Type
7.5.3 Spain Multiple Myeloma Market by Drug Type
7.6 Italy Multiple Myeloma Market
7.6.1 Italy Multiple Myeloma Market by End User
7.6.2 Italy Multiple Myeloma Market by Disease Type
7.6.3 Italy Multiple Myeloma Market by Drug Type
7.7 Rest of Europe Multiple Myeloma Market
7.7.1 Rest of Europe Multiple Myeloma Market by End User
7.7.2 Rest of Europe Multiple Myeloma Market by Disease Type
7.7.3 Rest of Europe Multiple Myeloma Market by Drug Type
Chapter 8. Company Profiles
8.1 Johnson & Johnson
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental &Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Trials and Approvals:
8.1.5.2 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Product Launches and Product Expansions:
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Trials and Approvals:
8.4 Amgen, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.4.5.2 Acquisition and Mergers:
8.5 AbbVie, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Baxter International, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.7 Teva Pharmaceutical Industries Ltd.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Product Launches and Product Expansions:
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional & Segmental Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.9 Bristol Myers Squibb Company
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Trials and Approvals:
8.9.5.2 Acquisition and Mergers:
8.10. Takeda Pharmaceutical Company Limited
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
Companies Mentioned
- Novartis AG
- Bristol Myers Squibb Company
- Amgen, Inc.
- AbbVie, Inc.
- Sanofi S.A.
- Johnson & Johnson
- Baxter International, Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
Methodology
LOADING...
